Agios Pharmaceuticals
AGIO
215 hedge funds and large institutions have $2.05B invested in Agios Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 86 increasing their positions, 77 reducing their positions, and 25 closing their positions.
34% more capital inflows, than outflows
Capital inflows: $202M | Capital outflows: $151M
30% more call options, than puts
Call options by funds: $11.2M | Put options by funds: $8.65M
12% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 77
1.63% more ownership
Funds ownership: 104.89% → 106.52% (+1.6%)
3% less funds holding
Funds holding: 221 → 215 (-6)
16% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 25
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Paradigm Biocapital Advisors
New York
|
+$34.6M |
| 2 |
TCG Crossover Management
Palo Alto,
California
|
+$21.1M |
| 3 |
Rock Springs Capital Management
Baltimore,
Maryland
|
+$19.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$12.1M |
| 5 |
Caligan Partners
New York
|
+$11.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Polar Capital Holdings
London,
United Kingdom
|
-$29.4M |
| 2 |
Armistice Capital
New York
|
-$26.7M |
| 3 |
State Street
Boston,
Massachusetts
|
-$15.1M |
| 4 |
BlackRock
New York
|
-$8.33M |
| 5 |
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$5.12M |
AGIO Hedge Fund Activity: Q2 2025 in Review
215 of the 7,624 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2025, worth a combined $2.05B — up 16% from $1.76B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of AGIO and 21 opened new positions — a net loss of 4 holders — while 77 trimmed existing stakes and 86 added.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $34.6M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $29.4M sold.
- 215 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2025, down from 221 in Q1 2025.
- Funds reported $2.05B of Agios Pharmaceuticals stock for Q2 2025, up 16% quarter-over-quarter.
- 21 funds opened new Agios Pharmaceuticals positions in Q2 2025 and 25 closed out, a net change of -4 holders.
- The largest Agios Pharmaceuticals buyer in Q2 2025 was Paradigm Biocapital Advisors, an estimated $34.6M added.
- The largest Agios Pharmaceuticals seller in Q2 2025 was Polar Capital Holdings, an estimated $29.4M sold.
Based on aggregated 13F filings for Q2 2025.